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WHAT’S IN A NAME? DEVELOPING
DEFINITIONS FOR COMMON HEALTH
TECHNOLOGY ASSESSMENT PRODUCT TYPES
OF THE INTERNATIONAL NETWORK OF
AGENCIES FOR HEALTH TECHNOLOGY
ASSESSMENT (INAHTA)
Tracy Merlin, David Tamblyn, Benjamin Ellery
and the INAHTA Quality Assurance Group
Adelaide Health Technology Assessment (AHTA), Discipline of Public Health, School of Population
Health, University of Adelaide
Objectives: A mapping exercise was undertaken to determine how HTA is being described and conducted across the International Network of Agencies for Health Technology
Assessment (INAHTA), with the aim of harmonizing terminologies and approaches.
Methods: Three progressive surveys were undertaken. In 2010, INAHTA agencies were asked to provide details on all of their HTA products. In 2013, additional information was
sought on key methodological characteristics of five of the most common HTA product types. Subsequently, final agreement was sought on three proposed product types.
Results: Forty-five HTA agencies responded to at least one of the surveys. In 2010, twenty-one agencies reported publishing over seventy named HTA products. Core domains
associated with full HTA reports were reported by a third of agencies but were labeled differently, so products were classified according to product type (n = 17). Agencies producing
short, tailored products increased between 2010 and 2013, with the publication of rapid reviews doubling from 33 percent to 66 percent. In 2013, half of the agencies adapted
their common HTA products from documents produced by other agencies. A consensus (>70 percent) was achieved on definitions for HTA reports, mini-HTAs, and rapid reviews.
Conclusions: The product label for an HTA is not always indicative of its content. Terminology has, therefore, been agreed to make explicit the trade-off between rigor and timeliness
in three common HTA product types. An INAHTA Product Type (IPT) Mark has been created to identify each of these. It is hoped this will further facilitate HTA adaptation between
agencies and reduce duplication of effort.
Keywords: Technology Assessment, Biomedical/standards, Technology Assessment, Biomedical/methods, Terminology as Topic, Policy Making/standards, Health Policy/standards
The Quality Assurance Group (QAG) was established in 2000
by the International Network of Agencies for Health Technol-
ogy (INAHTA) (1) to define and address issues concerning har-
monization of the health technology assessment (HTA) meth-
ods used among INAHTA’s fifty-seven public sector member
agencies.
INAHTA Quality Assurance Group Members: Jose´ Asua, Juan-Antonio Blasco, Elisabeth
Giesenhagen (Co-Chair), Christa Harstall, Erin Holmes, Groˆ Jamtvedt, Tracy Merlin (Co-Chair),
Sarvashni Moodliar, Jani Mueller, Michelle Mujoomdar, Skye Newton, David Tamblyn, and Nerys
Woolacott.
This research did not receive any funding and was the product of voluntary activity by INAHTA
Quality Assurance Group members. The authors thank those INAHTA members and agency
representatives (see Supplementary Table 4) who took the time to respond to one or more of the
surveys reported in this study. We thank Dr Vineet Juneja for his assistance with the data
extraction of the 2010 survey and to Sari Ormstadt, Ma˚ns Rosen, and Hans-Peter Dauben for
their contributions to the design of that survey. We also thank the current QAG members for their
contributions to the 2013 survey and for their comments on earlier drafts of the manuscript.
Although comprehensive standardization of methods is un-
likely to be applicable to all types of HTA products, it could
potentially reduce duplication of effort across member agen-
cies. Existing HTA products could be identified and simply
adapted to the local setting, and/or updated, rather than inde-
pendently produced. Greater standardization in HTA methods
through the specification of desirable approaches to conducting
different types of HTA, might facilitate this adaptation.
Harmonization efforts with respect to producing and adapt-
ing HTAs have been undertaken by other organizations, most
notably by the member agencies of the European Network for
Health Technology Assessment (EuNetHTA), some of whom
are members of INAHTA (2;3). Varying types of HTA prod-
ucts are recognized as part of the proposed harmonization pro-
cess but no formal definition has been applied to the different
products, instead the focus has been on identifying and ad-
dressing key aspects in specific modules (e.g., safety domain,
effectiveness domain, economic evaluation domain) and then
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applying or adapting modules as needed to meet local require-
ments (4).
There have been doubts raised with respect to how success-
ful harmonization efforts have been to date. Hutton et al. (2008)
have indicated that, although there is some degree of agreement
between researchers and practitioners on the principles of HTA,
there is still a lack of agreement on methodology details and
evidence standards (5). Trueman et al. (2009) when comparing
HTAs on drug eluting stents across jurisdictions found that “al-
though there is a common core data set considered by most of
the agencies, differences in the approach to HTA, heterogene-
ity of studies, and the limited relevance of research findings
to local practice meant that the core data set had only limited
influence on the resulting recommendations.” (6). Localizing
factors (e.g., local delivery of health care) are always going
to impact on policy decisions and so it would be surprising if
harmonization in HTA resulted in a harmonization of decision
making. What is concerning, however, is that the approaches to
the HTA, that is the methods used to evaluate the common core
data set, could contribute to the lack of harmonization between
HTAs.
HTAs are produced to be responsive to the decision maker
and so the approach to the HTA will necessarily be affected by
resource and time constraints. However, if it is clear at the outset
that a full HTA, for example, will always include an assessment
of the safety, effectiveness, economic evaluation, and organiza-
tional domains; that certain specific elements will be presented
in each of those domains; and that these specific elements will
be addressed to a minimum standard, then adaptation of mod-
ules from anHTA across jurisdictions and regions is more likely
to occur.
During the 2000 Annual Meeting of INAHTA, it was deter-
mined that methodologies for producing HTA products varied
amongmember organizations. The following year (2001) a draft
checklist was presented, that could serve both HTA developers
and the users of HTA (such as policy makers and individuals
within other HTA organizations), to identify what methods had
been used during the conduct of the HTA, and thus whether the
content would meet their needs (1). During a revision of this
checklist in 2007, it became apparent that what might be consid-
ered a “rapid review” by some agencies would be classified as
a “full HTA” by others, and some agencies were calling “mini-
HTAs,” “rapid reviews,” and vice versa. The QAG agreed that,
before the methods for performing HTAs could be internation-
ally harmonized, an understanding of the types and components
of HTA products performed by each member organization was
required. Simply, the QAG sought to classify all HTA prod-
ucts so that like-products could be compared under the same
appellation.
To assist this adaptation, a greater understanding of how
different agencies are conceptualizing and producing HTAs
and communicating the results of their HTAs to policy mak-
ers was needed. The first step to achieving this was to sur-
vey the INAHTA membership about the target audience,
content and methods used to develop their different HTA
products.
The ultimate aim would be to develop (i) some commonly
accepted definitions for the different HTA products and (ii)
benchmarks for different HTA products to achieve the QAG’s
goals of sharing knowledge, promoting collaboration, and re-
ducing duplication of effort in HTA.
METHODS
The initial paper-based survey was drafted by one of the au-
thors (TM) with input from the QAG and was disseminated
in May 2010. In terms of the survey structure and content,
twelve closed and open (free text) questions were used for
each HTA product. Agencies were asked to identify all of
their HTA products and to describe the methods and skills used
to create them (Supplementary Table 1, which can be viewed
online at http://dx.doi.org/10.1017/S0266462314000543). The
core HTA domains, as defined by Busse et al. (7), were used to
classify the content for each HTA product.
HTA products were categorized by two co-authors using a
stepped approach, that is, first, according to the provided product
label and, when that was not sufficiently explanatory, according
to the purpose of the product as described by the agency. It
was decided that the primary analysis would involve the most
commonly produced HTA products across the agencies. These
included full HTA reports, mini-HTAs, policy briefs, horizon
scanning reports, and rapid reviews.
In 2013, a Web-based follow-up survey was constructed
in Survey Monkey R© and distributed to members. It consisted
of twenty-two questions about the five common HTA product
types (Supplementary Table 2, which can be viewed online at
http://dx.doi.org/10.1017/S0266462314000543). Respondents
were able to skip questions if they were not relevant. Descrip-
tive analyses and graphs were generated using Excel 2007 R©
(MicrosoftTM).
On the basis of the 2013 survey results, definitions
were finalized for three of the product types (full HTA re-
ports, mini-HTAs, and rapid reviews) and presented at the
HTAi and INAHTA meetings in June 2013. A final three-
question survey was circulated to member agencies seek-
ing agreement with the proposed definitions (Supplementary
Table 3, which can be viewed online at http://dx.doi.org/
10.1017/S0266462314000543). Consensus was pre-defined
as reaching agreement by more than 70 percent of
respondents.
RESULTS
The paper-based 2010 survey achieved a response rate of
40 percent (21/53), despite active promotion at the annual
meeting and by the INAHTA Board. The Web-based 2013
follow-up survey had a response rate of 68 percent (38/56),
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Figure 1. Percentage of responding INAHTA agencies reporting the production of at least one of the below products (2010 survey).
while the short “agreement” survey had a response rate of
59 percent (33/56). Between 2010 and 2013, INAHTA had 53 to
56member agencies. Of these agencies, 45 responded to at least
one of the surveys (Supplementary Table 4, which can be viewed
online at http://dx.doi.org/10.1017/S0266462314000543). Ap-
proximately half of the respondents were from European coun-
tries, with the remainder spread throughout Oceania, Africa,
Asia, and the Americas. The results of the 2013 surveys are
reported throughout (given the better response rates), although
the 2010 survey results are reported for unique questions.
Purpose and Type of HTA Product
Overall, seventy named products were described by respondents
in the 2010 survey. Products that were not clearly designated as a
full HTA, mini-HTA, rapid review, or policy brief were reported
by a third of agencies as including all nine, or all of the first
five, core HTA domains (7), domains that are often associated
with full HTA reports. Thus, it was confirmed that the product
labelmay not always be indicative of product content. Seventeen
different product types were identified (Figure 1).
In both the 2010 and 2013 surveys, agencies reported that
their most common product was a full HTA report (16/21,
76 percent; and 30/38, 79 percent, respectively). However, the
publication of short, tailored HTA products increased, and in
some cases doubled, over the same period: rapid reviews were
produced by 7/21 (33 percent) agencies in 2010, compared with
25/38 (66 percent) of agencies in 2013; mini-HTAs were pub-
lished by 7/21 (33 percent) in 2010, compared with 23/36 (64
percent) in 2013; and policy briefs were disseminated by 7/21
(33 percent) of agencies in 2010, as opposed to 16/36 (44 per-
cent) in 2013.
The intended audience of the more common HTA product
types varied according to 2010 respondents and in some cases
thereweremultiple audiences intended for a product. According
to the agencies, policy makers were the most common target of
full HTA reports (88 percent), rapid reviews (86 percent) and
policy briefs (63 percent), but were less commonly the target of
mini-HTAs (56 percent). Mini-HTAs were primarily aimed at
health professionals.
Duration and Frequency of HTA Production
Agencies in 2013 reported that the average timeframes to pro-
duce different types of HTAwere 8.8 months for an HTA report,
2.9 months for a rapid review, 4 months for a mini-HTA, 2.8
months for a policy brief, and 2.8 months for an horizon scan-
ning report. As these averages could be skewed by a small num-
ber of large organizations with large output, median durations
and interquartile ranges are also given in Figure 2.
Among agencies that created at least one HTA product, the
most frequently produced was a rapid review, with 40 percent of
agencies (n = 25) producing more than ten a year. Mini-HTAs
were produced by 21 percent of agencies at a rate of more
than ten per year, with another 21 percent producing five per
year (n = 24). Full HTA reports were commonly produced but,
consistent with the complexity of a full HTA, the output was
less frequent. Most agencies reported publication of between
two and four full HTAs each year.
Core Domains Included in HTA Products
According to the 2013 survey, the four most common HTA
products are all likely to contain a description of the technol-
ogy, an overview of its current use, and information on its
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Figure 2. Production time-frames by HTA product type (2013 survey).
Figure 3. The likelihood that an agency always includes a “core domain” in the specified HTA products.
safety and effectiveness (Figure 3). More than 90 percent of
INAHTA agency respondents indicated that these domains are
present in full HTAs. In addition, 97 percent of agencies include
economic evaluations in their full HTAs—86 percent using
economic modeling and 89 percent providing financial (bud-
get) impact analyses. Eighty-one percent of agencies also in-
clude economic evaluations in their mini-HTAs but the propor-
tion using economic modeling is much smaller (38 percent),
with most of these agencies providing financial impact analy-
ses (67 percent). The other difference between full HTAs and
mini-HTAs is that the full version is much more likely to in-
clude information on the organizational, ethical, social and legal
core domains (Figure 3). Of these, the organizational domain
is addressed frequently in HTA reports. The social and legal
domains are the least likely to be included in any HTA product
type.
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Figure 4. The likelihood that an agency will include a type of systematic literature review in an HTA product type.
Patient and consumer involvement inHTAproduct develop-
ment appears to decrease as the length of time available to create
a product decreases. Forty-three percent of agencies producing
full HTA reports had no patient or consumer involvement, as
compared to 58 percent for mini-HTAs, 70 percent for rapid
reviews, 77 percent for policy briefs, and 92 percent for horizon
scanning reports.
Approaches Used in HTA Products
Approximately half of agencies reported adapting common
HTA products from those produced by other agencies, with the
exception of horizon scanning reports. Similarly, 61–79 percent
of agencies reported updating existing full HTA reports, mini-
HTAs, and rapid reviews, whether produced by their agency or
another agency. Original (primary) data were collected by some
agencies, usually to inform full HTA reports (46 percent) and
mini-HTAs (24 percent).
There was reasonable consensus across agencies with re-
spect to the methods of evidence synthesis used in full HTA re-
ports. Ninety-three percent of agencies would undertake a com-
prehensive systematic literature review (as defined in Figure 4),
while 30 percent would also consider restricting the review to
only high level evidence eg to systematic reviews or randomized
controlled trials. The least robust methods, including not per-
forming a systematic review, restricting the review to recent data
only, or of limiting the literature search to one or two databases,
were rarely considered (<10 percent of agencies) (Figure 4).
Agencies indicated they would use similar approaches to iden-
tify and synthesize information for mini-HTAs but would be
slightly more willing to undertake the less robust methodolo-
gies (albeit still less than 25 percent).
As can be seen in Figure 4, therewas a greater heterogeneity
of approaches when undertaking rapid reviews. Agencies were
more likely to consider riskier review methods that could miss
key information or allow bias to be introduced. Twenty-two
percent of agencies would not undertake a systematic review of
any type for rapid reviews.
Evidence Ascertainment
All agencies indicated that a complete search strategy would
always be reported in their full HTA reports, with enough detail
that the search could be replicated correctly in one database.
For mini-HTAs, this would be done by 66 percent of agencies.
This was less common for agencies doing rapid reviews (44 per-
cent) and horizon scanning reports (42 percent). The databases
searched by agencies writing full and mini-HTA reports were
very similar. Agencies performing rapid reviews would also
search similar databases, with the exception of those dealing
exclusively with economics literature. More than 75 percent
of agencies writing full and mini-HTA reports and rapid re-
views used the HTA database, the Cochrane Library, Medline,
or PubMed. Embase was more commonly used by agencies
writing full HTA reports (83 percent), than mini-HTAs (74 per-
cent), or rapid reviews (65 percent). The EuroScan database
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(79 percent) and PubMed (86 percent) were the main sources
of information for those writing horizon scanning reports.
More than half of agencies used seven sources of informa-
tion for their full HTA reports, mini-HTAs, and horizon scan-
ning reports; with six sources of information used for rapid
reviews.
Extraction and Appraisal of Evidence
All agencies (n = 30) indicated that a critical appraisal tool
or checklist was used some or all of the time to ascertain the
quality of studies included in full HTA reports. Similar results
were obtained for agencies undertakingmini-HTAs (96 percent,
n = 24). Critical appraisal was not undertaken by a substantial
proportion of agencies producing rapid reviews (33 percent, n
= 27), policy briefs (66 percent, n = 16) and horizon scanning
reports (43 percent, n = 14).
Evidence tables are always presented by 83 percent, 67 per-
cent, and 41 percent of agencies, respectively, in their full HTA
reports, mini-HTAs, or rapid reviews. Data elements included
by agencies in these evidence tables were very similar, irrespec-
tive of HTA product type. The least common domains appear to
be the clinical importance and applicability (external validity)
of study results. It may be that this is done narratively, when
the findings from the evidence are interpreted within the local
policy context.
Proposing Product Type Definitions
On the basis of the results of the 2013 survey, definitions were
proposed for three of the product types: full HTA reports, mini-
HTAs, and rapid reviews. It was decided that a content definition
for policy briefs would be unrealistic given that they tend to be
secondary products that could summarize the results of any
other HTA product. A content definition for horizon scanning
reports was also considered unrealistic as they also vary widely
in scope according to the available evidence base.
The INAHTA members were asked to indicate their agree-
ment with the proposed content definitions (see the Discussion
section) for the three product types, in a final survey (Supple-
mentary Table 3). Consensus was achieved as more than 70
percent of respondents agreed with the definitions proposed for
HTA reports, mini-HTAs, and rapid reviews.
DISCUSSION
One of the aims of the INAHTA Quality Assurance Group
(QAG) is to create a shared international understanding of HTA.
It has become apparent that a barrier to discussing and quality
assuring the methods used for HTA products is that there is no
common naming convention or categorization of HTA product
types.
Our survey results indicate that the proportion ofHTA agen-
cies producing short, tailored products has doubled over a 4-year
period. Seventy distinct HTA products and seventeen product
typeswere already being produced by twenty-oneHTA agencies
in 2010. The range of products and product types available sug-
gests that agencies are appropriately developing products that
target specific policy-maker audiences and address the prefer-
ences of policy makers for different types of information. Both
macro and micro perspectives on a health technology are often
needed (8).
It is clear that the names attributed to HTA products
can often describe what the product is used for rather than
what the product contains. Consequently, two similar prod-
ucts could be given entirely different names primarily be-
cause one is aimed at policy makers and the other at
clinicians.
Some organizations have produced their own definitions
for different HTA products. For example, DACEHTA first de-
veloped mini-HTAs and defined them as a management and
decision support tool or checklist with the primary purpose of
informing the introduction of new health technologies within
the hospital setting. This is consistent with the fact that the pri-
mary audience of mini-HTAs in our 2010 survey were health
professionals. The original aim of a mini-HTA was to cover
the components of a full HTA report but in an abbreviated for-
mat so that the assessment could be completed within a short
time frame (9). However, it is apparent from the current sur-
vey that some organizations consider that an HTA within a
short timeframe is a rapid review, while others produce mini-
HTAs that are intended for policy makers and are simply full
HTA reports minus the social, ethical, legal, and organizational
considerations.
The HTA adaptation toolkit produced by EUnetHTA pro-
poses a modularized approach for adapting an HTA to the local
setting (4). However, this would be simpler if it is clear as to
the type of HTA that is being adapted, and also if the HTA
product type is associated with a standard approach and ac-
cepted methods. Milne et al. (2011) state, “Clearly, the more
information, data and explanation provided in the HTA re-
port for adaptation, the easier and more comprehensive the
adaptation process. Thus, the toolkit would be best used as
an aid to adapting more comprehensive HTA reports. How-
ever, it can also be used to adapt information and data from
“rapid reviews” and “mini-HTAs” but the user will need to be
aware of the purpose, and potential limitations, of the original
report.”
Accepted Definitions
The QAG surveys have provided valuable insight into the
HTA products developed by INAHTA member agencies. The
definitions proposed and accepted (below) for the most com-
mon of these products were based solely on the results of the
surveys and thus reflect themethods and approaches that are cur-
rently used by INAHTA agencies. In the statements below, the
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asterisk denotes the HTA Glossary (htaglossary.net) definition
of a systematic review.
1. An HTA Report will
• Always
° describe the characteristics and current use of the technology
° evaluate safety and effectiveness issues
° determine the cost-effectiveness of the technology eg through eco-
nomic modeling (when it is appropriate)
° provide information on costs/financial impact, and
° discuss organizational considerations.
• Always conduct a comprehensive systematic literature review∗ or a sys-
tematic review of high level evidence.
• Always critically appraise the quality of the evidence base.
• Optionally address ethical, social and legal considerations.
2. A Mini-HTA will:
• Always
° describe the characteristics and current use of the technology
° evaluate safety and effectiveness issues, and
° provide information on costs/financial impact.
• Always conduct a comprehensive systematic literature review∗ or a sys-
tematic review of high level evidence.
• Always critically appraise the quality of the evidence base.
• Optionally address organizational considerations.
3. A Rapid Review will:
• Always
° describe the characteristics and current use of the technology, and
° evaluate safety and effectiveness issues.
• Often conduct a review of only high level evidence or of re-
cent evidence and may restrict the literature search to one or two
databases.
• Optionally critically appraise the quality of the evidence base.
• Optionally provide information on costs/financial impact.
The impetus toward the development of minimum standards in
HTA reflects, to some extent, similar moves by the Cochrane
Collaboration (10) and the Guidelines International Network
(11) towards minimum standards and consistency in their prod-
ucts. It is important that all producers of HTA concur in their
understanding of at least the commonHTAproduct types. These
definitions can guide future development of products by newer
agencies and assist the large proportion of INAHTA agencies
that adapt or update other agency’s products for their local con-
text.
It was apparent from the survey results that HTA reports
have the greatest rigor and complexity of all products and pro-
vide the most amount of information. Mini-HTAs maintain the
rigor but have a restricted scope and provide less information
than full HTA reports. Rapid reviews, on the other hand, have
the least rigor and the smallest scope, a likely consequence of
the truncated timeline for production. Although timelines did
vary substantially between agencies, rapid reviews tend to take
an average of 1 month less to produce than mini-HTAs. There-
fore, if the policy decision is important, it would appear that
the less risky alternative (i.e., in terms of ensuring conclusions
are fully informed) would be to wait a little longer for the mini-
HTA to be produced. For decisions that have serious policy
implications, the least risky strategy would be to commission a
full HTA report. However, if the intended audience of an HTA
is only seeking information, prioritizing activities or determin-
ing options, rather than formulating a fixed policy, then a rapid
review might be the most cost-effective option.
INAHTA Product Type Mark
The name or title of an HTA product can be as varied as the
70 identified for the 2010 survey, but if the product type is
unambiguously defined then stakeholders will have a clear un-
derstanding of the approaches used in the HTA and this may
inform collaborative or adaptive arrangements or simply make
the policy maker aware of the benefits or limitations inherent in
the chosen product type.
To operationalize these agreed definitions, the INAHTA
QAG received Board approval to develop an INAHTA Product
Type (IPT) Mark that indicates conformity with the INAHTA
defined product type. INAHTA members create many more
products than are encompassed by the agreed three product
types but at least the IPT Marks will be able to be used for
these common ones. The IPT Mark will be available for down-
load from the members’ only section of the INAHTA Web site
(www.inahta.org) and can be inserted by member agencies on
the front cover or inside front cover of their documents. This
will help readers determine at a glance, irrespective of language
and naming conventions, the content and methods used in the
HTA product.
There are two IPT Mark options for each product type: one
that indicates the product type designation has been indepen-
dently verified, and one other that does not mention independent
verification. The two options were provided in the event that
an INAHTA member cannot find another independent member
agency to verify that the document meets the INAHTA defini-
tion (e.g., due to language considerations).
Study Limitations
The applicability of the 2010 survey results is limited by the
poor response rate, despite the response being similar to other
surveys done of INAHTA agencies (12;13). However, the more
comprehensive survey undertaken in 2013 had a good response
rate and so the findings are more likely to be applicable to non-
responding INAHTA agencies. Forty-five INAHTA agencies
participated overall, and this is a significant proportion of the
53–56 agencies that were members between 2010 and 2013.
The extent to which the survey results obtained from not-
for-profit or public sector HTA agencies, a requirement for IN-
AHTA membership, are generalizable to all HTA agencies is
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uncertain.While the jurisdictional context in which HTA is pro-
duced and the resources available necessarily affect the content
and approach to HTA, this should not be a deterrent to pro-
viding guidance and frameworks for creating HTA (1). Those
agencies who responded to the survey included developing and
developed economies, and representatives from Europe, south-
ern Africa, the middle-east, Asia, Oceania, and the Americas
(North, Central, and South).
POLICY IMPLICATIONS OF THIS RESEARCH
HTA products differ across agencies, both in nomenclature and
the methods used to create them. However, contextual differ-
ences and regional nuances which are important to individual
agencies and the policy makers they target, as well as the pro-
liferation of HTA products, will present a barrier to achieving
the harmonization required to adapt or translate HTA findings
across agencies and countries. On analyzing the survey results,
it is obvious that certain products created by INAHTA agencies
are produced with similar broadly defined methods and address
similar core domains. However, the product label for an HTA
is not always indicative of the product content. Evidence-based
working definitions for each of the three common product types
have been proposed and accepted by INAHTA members. The
use of an IPT Mark to distinguish between these three product
types, without requiring a name change of individual products
or an understanding of the language, will assist with harmoniza-
tion and quality assurance. This will enable easier identification,
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